Table 1 Baseline characteristics and key demographics (SURPASS 1–5 individual [pooled arms] and pooled data)
Individual SURPASS trials | Pooled SURPASS trials | ||||||
|---|---|---|---|---|---|---|---|
SURPASS-1 (N = 478) | SURPASS-2 (N = 1878) | SURPASS-3 (N = 1437) | SURPASS-4 (N = 1995) | SURPASS-5 (N = 475) | Pooled TZP (N = 4199) | Pooled comparator (N = 2064) | |
Age (years) | 54.1 ± 11.9 | 56.6 ± 10.4 | 57.4 ± 10.0 | 63.6 ± 8.6 | 60.6 ± 9.9 | 58.5 ± 10.4 | 60.3 ± 10.3 |
Sex—male (n, %) | 247 (51.7) | 882 (47.0) | 802 (55.8) | `1246 (62.5) | 264 (55.6) | 2245 (53.5) | 1196 (57.9) |
Duration of diabetes (years) | 4.7 ± 5.4 | 8.6 ± 6.5 | 8.4 ± 6.2 | 11.8 ± 7.5 | 13.3 ± 7.3 | 9.38 ± 7.0 | 10.12 ± 7.3 |
Cardiovascular disease (%)a | 5 | 8 | 13 | 87 | 18 | 35 | 35 |
HbA1c (%) | 7.9 ± 0.9 | 8.3 ± 1.0 | 8.2 ± 0.9 | 8.5 ± 0.9 | 8.3 ± 0.9 | 8.3 ± 1.0 | 8.3 ± 0.9 |
BMI (kg/m2) | 31.9 ± 6.6 | 34.2 ± 6.9 | 33.5 ± 6.1 | 32.6 ± 5.5 | 33.4 ± 6.1 | 33.4 ± 6.3 | 33.0 ± 6.1 |
Weight (kg) | 85.9 ± 19.8 | 93.7 ± 21.9 | 94.3 ± 20.1 | 90.3 ± 18.7 | 95.2 ± 21.6 | 92.6 ± 20.6 | 91.6 ± 20.1 |
eGFR (mL/min/1.73m2) | 94.1 ± 19.7 | 96.0 ± 17.1 | 94.1 ± 17.0 | 81.3 ± 21.1 | 85.5 ± 17.8 | 91.0 ± 19.5 | 87.8 ± 20.3 |
SBP (mmHg) | 127.6 ± 14.1 | 130.6 ± 13.8 | 131.5 ± 13.3 | 134.4 ± 15.4 | 137.9 ± 15.7 | 132.0 ± 14.5 | 133.1 ± 14.9 |
DBP (mmHg) | 79.4 ± 8.8 | 79.2 ± 9.0 | 79.2 ± 8.9 | 78.4 ± 9.4 | 80.7 ± 10.8 | 79.0 ± 9.2 | 79.1 ± 9.4 |
Antihypertensive medication use (%)b | 47 | 64 | 70 | 93 | 75 | 72 | 78 |
ACE inhibitors | 13 | 30 | 33 | 40 | 36 | 32 | 35 |
Angiotensin II receptor blockers | 22 | 26 | 21 | 37 | 27 | 27 | 30 |
Dihydropyridine derivatives | 11 | 12 | 17 | 27 | 30 | 18 | 21 |
Beta-blocking agents | 7 | 11 | 23 | 41 | 30 | 22 | 28 |